Premium
The effect of granulocyte—macrophage colony‐stimulating factor (GM‐CSF) on hepatitis B vaccination in haemodialysis patients
Author(s) -
Hess G.,
Kreiter F.,
Kösters W.,
Deusch K.
Publication year - 1996
Publication title -
journal of viral hepatitis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.329
H-Index - 100
eISSN - 1365-2893
pISSN - 1352-0504
DOI - 10.1111/j.1365-2893.1996.tb00006.x
Subject(s) - medicine , hbsag , immunology , granulocyte macrophage colony stimulating factor , vaccination , hepatitis b vaccine , hepatitis b , booster dose , adverse effect , antibody , gastroenterology , titer , hepatitis b virus , cytokine , virus
Summary Haemodialysis patients often fail to respond to hepatitis B vaccination. In this pilot study, 15 patients previously non‐responsive to at least three 40 μg doses of hepatitis B vaccine were given 0.5, 5 or 10μg kg ‐1 granulocyte‐macrophage colony‐stimulating factor (GM‐CSF) subcutaneously 24 h prior to booster vaccination with a hepatitis B vaccine. Seven of the 15 patients developed antibody to hepatitis B surface antigen (HBsAb) (35–7240 IU L ‐1 ) upon initial vaccination with GM‐CSF and two of four individuals responded with low HBsAb titres of 15 and 60 IU L ‐1 when revaccinated with hepatitis B surface antigen (HBsAg) and twice the dose of GM‐CSF. The application of GM‐CSF was associated with adverse effects that were, in general, mild to moderate in severity and appeared to be dose dependent. Two patients, both receiving 10 μg kg ‐1 GM‐CSF discontinued the study because of severe hypotension.